Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver to discuss the company receiving positive feedback from Health Canada on the Company’s plan for a Phase Two COVID-19 clinical study in Canada, with its repurposed drug Ifenprodil. Moreau explains what that study will look like and he also discusses a similar program in South Korea.
Full interview: Algernon Pharmaceuticals receives positive feedback from Health Canada for Ifenprodil
Quick facts: Algernon Pharmaceuticals Inc.
Price: 0.325 CAD
Market Cap: $29.27 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE